Endo International PLC (ENDP) Scheduled to Post Quarterly Earnings on Thursday
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 9th. Analysts expect the company to announce earnings of $0.66 per share for the quarter.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.86 earnings per share. On average, analysts expect Endo International PLC to post $4 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of Endo International PLC (NASDAQ ENDP) opened at $5.93 on Wednesday. The firm has a market cap of $1,390.00, a price-to-earnings ratio of 1.28 and a beta of 0.53. The company has a current ratio of 1.02, a quick ratio of 0.80 and a debt-to-equity ratio of 10.20. Endo International PLC has a 1-year low of $5.77 and a 1-year high of $18.63.
ENDP has been the topic of a number of research analyst reports. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Endo International PLC in a report on Thursday, September 28th. They set a “sell” rating and a $7.00 price objective on the stock. Piper Jaffray Companies reissued a “hold” rating and set a $9.00 price objective on shares of Endo International PLC in a report on Sunday, September 17th. Mizuho reissued a “buy” rating and set a $14.00 price objective (down from $19.00) on shares of Endo International PLC in a report on Tuesday, September 12th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a report on Tuesday, August 8th. Finally, Zacks Investment Research lowered shares of Endo International PLC from a “buy” rating to a “hold” rating in a report on Thursday, October 12th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $12.64.
In other news, CEO Paul Campanelli acquired 6,500 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was acquired at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the transaction, the chief executive officer now owns 213,620 shares in the company, valued at approximately $1,647,010.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Terrance J. Coughlin acquired 20,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was purchased at an average price of $7.70 per share, with a total value of $154,000.00. Following the transaction, the chief operating officer now owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 36,000 shares of company stock valued at $279,460. Insiders own 0.50% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.